Vertex Pharmaceuticals Incorporated
VRTX
$472.43
-$5.46-1.14%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.95B | 3.68B | 3.64B | -988.90M | -535.60M |
| Total Depreciation and Amortization | 178.60M | 175.40M | 174.60M | 176.90M | 182.00M |
| Total Amortization of Deferred Charges | 31.20M | 25.20M | 25.20M | 25.20M | 25.20M |
| Total Other Non-Cash Items | 667.50M | 653.80M | 812.60M | 719.10M | 350.60M |
| Change in Net Operating Assets | -1.20B | -811.50M | -803.60M | -912.60M | -514.80M |
| Cash from Operations | 3.63B | 3.72B | 3.85B | -980.30M | -492.60M |
| Capital Expenditure | -437.60M | -380.80M | -346.70M | -270.00M | -297.70M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -507.80M | -1.10B | -1.36B | -1.42B | -3.47B |
| Cash from Investing | -945.40M | -1.48B | -1.71B | -1.69B | -3.77B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -5.40M | -5.30M | -9.30M | -21.70M | -33.60M |
| Issuance of Common Stock | 127.70M | 108.00M | 108.50M | 114.40M | 114.60M |
| Repurchase of Common Stock | -2.39B | -2.68B | -1.91B | -1.91B | -1.58B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.70M | 3.50M | 3.30M | 3.50M | 6.20M |
| Cash from Financing | -2.26B | -2.58B | -1.81B | -1.82B | -1.49B |
| Foreign Exchange rate Adjustments | 90.90M | 36.30M | 63.20M | 3.50M | -42.60M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 515.60M | -300.30M | 391.00M | -4.48B | -5.80B |